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 In 2002 the National Kidney Foundation 
Kidney Disease Outcomes Quality Initia-
tive (KDOQI) Work Group defined 
chronic kidney disease (CKD) as the 3-
month presence of proteinuria or a per-
sistently lowered glomerular ' ltration rate 
(GFR) regardless of the underlying pathol-
ogy. According to this de' nition, almost 
20 million adults in the United States have 
CKD, and yet another 20 million are con-
sidered at risk for developing CKD. 
Because of its growing prevalence and its 
high socioeconomic burden, CKD has 
recently been termed the  ‘ silent epidemic. ’ 
2 e course of CKD is marked by second-
ary complications such as bone disease 
and anemia as well as a considerably 
increased risk for cardiovascular disease 
and, in a minority of patients, the 
progression to end-stage renal disease . 
 Age, background cardiovascular risk, 
and the etiology of kidney disease have all 
been described as impacting the progres-
sion of the disease independent of baseline 
CKD stage. A recent study by O ’ Hare  et al. 
convincingly demonstrated the 4 aws of a 
purely GFR-based approach to CKD 
patients by showing a tenfold increase in 
the ratio of necessary to unnecessary vas-
cular access surgery in elderly patients. 1 A 
GFR-independent marker of disease pro-
gression would help clinicians to tailor 
therapy and intervention and to base their 
decisions on the individual patient ’ s risk. 
 Dieplinger  et al. 2 (this issue) describe the 
ability of pro-A-type natriuretic peptide and 
pro-adrenomedullin to predict disease pro-
gression in patients with nondiabetic kidney 
disease enrolled in the Mild to Moderate 
Kidney Disease (MMKD) Study. 
 A-type natriuretic peptide (ANP) is a car-
diac peptide with potent natriuretic, vasodi-
lator, and diuretic actions. ANP stems from 
the enzymatic cleavage of its precursor 
proANP, which is signi' cantly more stable 
than the active breakdown product. 2 e co-
released, inactive N-terminal split product 
is subject to further enzymatic fragmenta-
tion, leaving the midregional breakdown 
product MR-proANP as a stable and readily 
measurable parameter of circulating ANP 
levels. ANP is primarily secreted from the 
cardiac atria in response to volume over-
load and myocyte stretch. Increased levels 
of ANP have been observed in heart failure, 
le:  ventricular dysfunction, coronary artery 
disease, and renal failure. 
 Adrenomedullin (ADM) is also a potent 
natriuretic and vasodilatory peptide. It has a 
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 The interplay between the heart and the kidneys has received 
widespread attention in recent years.  A novel five-class definition of 
cardiorenal syndromes has been proposed. The ability of two markers of 
cardiac dysfunction to predict progression of primary kidney disease, 
described by Dieplinger and his co-workers, highlights the prognostic 
importance of the chronic cardiorenal (types 2 and 4) syndromes. 
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short half-life and is derived from the cleav-
age of a larger precursor molecule, proADM. 
MR-proADM is stable at room temperature 
and can be measured by a sandwich immu-
noassay. MR-proADM directly re4 ects cir-
culating adrenomedullin levels. Increased 
adrenomedullin levels have been observed 
in disorders associated with hypervolemia, 
such as heart failure, myocardial infarction, 
and ESRD under hemodialysis. Pathologi-
cally increased adrenomedullin levels were 
recently shown to reflect the degree of 
underlying cardiac dysfunction. 3,4 While 
adrenomedullin has been detected in multi-
ple tissues, disease-induced secretion appears 
to stem from biventricular cardiac dilation 5 
and increased vascular shear stress. 6 
 During the 7-year follow-up period cov-
ered in the MMKD Study, the combined 
end point of a doubling of serum creatinine 
or disease progression to ESRD requiring 
renal replacement therapy was reached in 
65 of 177 patients. In accordance with pre-
vious studies, Dieplinger  et al. 2 found 
patients reaching this end point to be older 
and to display higher levels of proteinuria 
and lower GFR. Additionally, the authors 
reported higher levels of MR-proANP and 
MR-proADM in progressors. 2 e predic-
tive accuracy of these novel biomarkers 
was equal to the predictive potential of 
baseline GFR values (AUC MR-proANP  =  0.810, 
AUC MR-proADM  =  0.876, AUC GFR  =  0.838). 
Remarkably, MR-proANP and MR-
proADM retained high diagnostic accuracy 
even after the adjustment for the most 
common cofactors for disease progression: 
age, sex, GFR, and proteinuria. These 
results suggest that MR-proANP and MR-
proADM, two reliable markers of cardiac 
dysfunction, could help clinicians to 
estimate the pace of disease progression, 
even in patients with equal GFR and 
proteinuria levels. 
 2 is study extends and corroborates 
similar ' ndings from the same cohort for 
NT-proBNP, a quantitative marker of car-
diac stress that is released predominantly 
by the cardiac ventricles. BNP and 
NT-proBNP are co-secreted and, under 
non-stressed conditions, are found only 
in atrial granules. In response to stress, 
however, BNP and NT-proBNP are syn-
thesized, stored, and released mainly from 
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 Hence, the ability of two markers of 
cardiac dysfunction to predict progres-
sion of primary kidney disease, described 
by Dieplinger and his co-workers, 2 high-
lights the prognostic importance of the 
chronic cardiorenal syndromes (CRS 
types 2 and 4). 
 Unfortunately, this obvious pathophys-
iological link between CKD and cardiac 
dysfunction is confronted by a signi' cant 
underprescription of cardiovascular dis-
ease-modifying pharmacotherapy in CKD 
patients. A recent, alarming study inves-
tigating patients a: er acute myocardial 
infarction found less than 50 % of all CKD 
patients to be treated with a combination 
of aspirin, beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, and 
statins. 9 Only the minority of CKD 
patients receiving standard combination 
drug therapy experienced 30-day survival 
similar to that of non-CKD patients. 2 is 
lack of guideline-conforming therapy is 
generally caused by concerns over increas-
ing creatinine levels and potential nephro-
ventricular myocardium. The primary 
stimulus for BNP and NT-proBNP forma-
tion seems to be end-diastolic wall stress. 
 One important limitation, which was 
appropriately acknowledged by the authors, 
is the lack of detailed functional and struc-
tural cardiac assessment (for example, 
echocardiography) and therefore the inabil-
ity to elucidate whether MR-proANP and 
MR-proADM were associated with CKD 
progression independently of the presence 
of structural and / or functional cardiac dis-
ease or whether clinically undetected car-
diac disease at least to some extent triggered 
the deterioration of renal function. 
 2 e interplay between the heart and the 
kidneys has received widespread attention 
in recent years (Figure 1). Initially, the  ‘ car-
diorenal syndrome ’ has generally been con-
sidered to be driven by a failing heart 
causing a secondary deterioration of kidney 
function. In this setting, impaired kidney 
function has convincingly been shown to 
be associated with a signi' cantly reduced 
patient survival. 2 is simplistic and uni-
directional view has recently been challenged 
a: er accelerated cardiac atherosclerosis, le:  
ventricular hypertrophy and remodeling, 
and myocardial microangiopathy were 
observed in primary kidney diseases. 7 
 To accommodate these important 
kidney – heart interactions, a novel ' ve-
classed definition of cardiorenal syn-
dromes (CRS) has been proposed. 8 In this 
classi' cation, types 1 and 2 represent the 
acute and chronic forms of the  ‘ classic ’ 
cardiorenal syndrome, in which decreased 
cardiac function induces a progressive 
and potentially permanent decline in kid-
ney function. Similarly, types 3 and 4 rep-
resent the acute and chronic forms of the 
 ‘ renocardiac ’ syndrome, in which primary 
kidney disease induces acute (for example, 
heart failure, arrhythmia) or chronic (for 
example, hypertrophy, coronary athero-
sclerosis) cardiac disorders. An additional 
type 5 includes systemic diseases such as 
sepsis, amyloidosis, and systemic lupus 
erythematosus that are able to induce car-
diac as well as renal dysfunction. 
 Figure 1  |  Cardiorenal interactions. 
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toxicity. However, a short-term, ACE 
inhibitor-associated increase in serum 
creatinine was found to re4 ect successful 
nephroprotection in patients with renal 
insuJ  ciency by a large metaanalysis. 10 
 While research activities in the cardio-
renal syndromes are only beginning to 
grow and consensus de' nitions are only 
being discussed, clinicians may presently 
not be able to stop the vicious cycle of 
declining renal and cardiac function but 
can nevertheless signi' cantly slow down 
its progression. Treating the shared risk 
factors by adequately lowering blood pres-
sure and suJ  ciently blocking the renin –
 angiotensin system as well as by controlling 
diabetes mellitus, treating dyslipidemia, 
and advocating smoking cessation remains 
of pivotal importance. We as clinicians 
need to consider and attempt to use these 
powerful tools in all our CRS patients. 
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 Dysregulated production of nitric oxide 
(NO) is a key event in the development of 
endothelial dysfunction. Endothelial NO 
production by endothelial NO synthase 
(eNOS) is not only paramount for the relax-
ation of vascular smooth muscle and preven-
tion of its excessive proliferation but is also 
important as a deterrent to platelet aggrega-
tion and leukocyte – endothelial adhesion 
and transmigration. 2 ese actions of NO 
underlie its role in the defense against athero-
sclerosis and its complications. Usually, the 
functional uncoupling of eNOS leads to 
reduced NO availability and endothelial dys-
function due to the preferential generation 
of superoxide and peroxynitrite. In addition, 
the human eNOS gene contains multiple 
polymorphic sites, such as single-nucleotide 
polymorphisms, dinucleotide repeats, and a 
variable number of tandem repeats, some of 
which may have functional consequences. 
2 e most commonly detected and investi-
gated polymorphisms are T786C in the pro-
moter region, eNOS4b / 4a in intron 4, 
and G894T (Glu298Asp) in exon 7. Epide-
miologic studies variably link these 
polymorphisms with increased risk for 
atherosclerosis, myocardial infarction, and 
coronary heart disease. 1 2 e multitude of 
polymorphic sites in the gene poses three 
important problems: on the one hand, poly-
morphisms need to be characterized in eth-
nically divergent populations, 1 and on the 
other, each polymorphism has to be evalu-
ated functionally as a harbinger of potential 
diseases (tasks accomplished by a large body 
of studies recently subjected to metaanaly-
sis 2 ); furthermore, for those polymorphisms 
that are found to be clinically meaningful, 
the molecular defect or defects need to be 
identi' ed. 2 e latter task is most diJ  cult, 
especially in considering the function of an 
enzyme as complex as eNOS. 
 Cherney and co-workers 3 (this issue) 
have attempted to accomplish this task by 
focusing on the functional characterization 
of the G894T eNOS polymorphism in a 
selected group of apparently healthy sub-
jects harboring the T allele. 2 e investiga-
tors used  L -arginine infusion as a challenging 
tool and induced changes in renal hemo-
dynamics as readout parameters. While 
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 Cherney and co-workers examine the functional phenotype of the 
G894T eNOS polymorphism in a selected group of apparently healthy 
subjects. The investigators used  L -arginine infusion and induced 
changes in renal hemodynamics. While  L -arginine increased effective 
plasma flow and glomerular filtration rate in GG subjects, these 
responses were blunted in GT / TT subjects, suggesting that either the 
G894T polymorphism impairs eNOS function, or GG subjects exhibit 
augmented eNOS responsiveness to  L -arginine. The complexity of this 
seemingly straightforward conclusion deserves elaboration. 
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